3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sezary Syndrome
1
Sarcoma, Synovial
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Mycosis Fungoides
1
Liposarcoma, Myxoid
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
128
Radiotherapy
85
Bevacizumab
43
Radiation
30
Carmustine
29
Irinotecan
25
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
sargramostim
12
Radiotherapy, Intensity-Modulated
12
Radiotherapy, Conformal
12
Sirolimus
10
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
pembrolizumab
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
Gefitinib
8
motexafin gadolinium
7
aldesleukin
7
Procarbazine
7
Gene Expression Profiling
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
interferon gamma-1b
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled